Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT

被引:300
作者
Yin, Lei [1 ]
Li, Hui [2 ]
Li, Ai-Jun [1 ]
Lau, Wan Yee [1 ,3 ]
Pan, Ze-ya [1 ]
Lai, Eric C. H. [1 ,3 ]
Wu, Meng-chao [1 ]
Zhou, Wei-Ping [1 ]
机构
[1] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai 200438, Peoples R China
[2] Second Mil Med Univ, Changhai Hosp, Dept Dermatol, Shanghai 200438, Peoples R China
[3] Chinese Univ Hong Kong, Fac Med, Shatin, Hong Kong, Peoples R China
关键词
Multiple hepatocellular carcinoma; Partial hepatectomy; Transcatheter arterial chemoembolization; Overall survival; RCT; TRANSARTERIAL CHEMOEMBOLIZATION; CYTOREDUCTIVE SURGERY; MULTIDISCIPLINARY TREATMENT; MICROVASCULAR INVASION; PROGNOSTIC-FACTORS; REDUCTION SURGERY; HEPATIC RESECTION; ELUTING BEADS; EPIDEMIOLOGY; PREDICTION;
D O I
10.1016/j.jhep.2014.03.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: The aim of this randomized comparative trial (RCT) is to compare partial hepatectomy (PH) with transcatheter arterial chemoembolization (TACE) to treat patients with resectable multiple hepatocellular carcinoma (RMHCC) outside of Milan Criteria. Methods: This RCT was conducted on 173 patients with RMHCC outside of Milan Criteria (a solitary tumor up to 5 cm or multiple tumors up to 3 in number and up to 3 cm for each tumor) who were treated in our centre from November 2008 to September 2010. The patients were randomly assigned to the PH group or the TACE group. The primary outcome measure was overall survival (OS) from the date of treatment. A multivariate Cox proportional hazards regression analysis was performed to assess the prognostic risk factors associated with OS. Results: The 1-, 2-, and 3-year OS rates were 76.1%, 63.5%, and 51.5%, respectively, for the PH group compared with 51.8%, 34.8%, and 18.1%, respectively, for the TACE group (Log-rank test, X-2 = 24.246, p <0.001). Multivariate Cox proportional hazards regression analysis revealed the type of treatment (hazard ratio, 0.434; 95% CI, 0.293 to 0.644, p <0.001), number of tumor (hazard ratio, 1.758; 95% CI, 1.213 to 2.548,p = 0.003) and gender (hazard ratio, 0.451; 95% CI, 0.236 to 0.862, p = 0.016) were significant independent risk factors associated with OS. Conclusions: PH provided better OS for patients with RMHCC outside of Milan Criteria than conventional TACE. The number of tumor and gender were also independent risk factors associated with OS for RMHCC. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:82 / 88
页数:7
相关论文
共 33 条
  • [1] Epidemiology of primary liver cancer
    Bosch, FX
    Ribes, J
    Borràs, J
    [J]. SEMINARS IN LIVER DISEASE, 1999, 19 (03) : 271 - 285
  • [2] Prognostic prediction and treatment strategy in hepatocellular carcinoma
    Bruix, J
    Llovet, JM
    [J]. HEPATOLOGY, 2002, 35 (03) : 519 - 524
  • [3] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [4] Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design
    Burrel, Marta
    Reig, Maria
    Forner, Alejandro
    Barrufet, Marta
    Rodriguez de Lope, Carlos
    Tremosini, Silvia
    Ayuso, Carmen
    Llovet, Josep M.
    Isabel Real, Maria
    Bruix, Jordi
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (06) : 1330 - 1335
  • [5] Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: Univariate and multivariate analysis
    Chen, MF
    Tsai, HP
    Jeng, LB
    Lee, WC
    Yeh, CN
    Yu, MC
    Hung, CM
    [J]. WORLD JOURNAL OF SURGERY, 2003, 27 (04) : 443 - 447
  • [6] CHEN MF, 1989, ARCH SURG-CHICAGO, V124, P1025
  • [7] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
  • [8] Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study
    Dhanasekaran, Renumathy
    Kooby, David A.
    Staley, Charles A.
    Kauh, John S.
    Khanna, Vinit
    Kim, Hyun S.
    [J]. HPB, 2010, 12 (03) : 174 - 180
  • [9] Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
    El-Serag, Hashem B.
    Rudolph, Lenhard
    [J]. GASTROENTEROLOGY, 2007, 132 (07) : 2557 - 2576
  • [10] Hepatocellular carcinoma
    Forner, Alejandro
    Llovet, Josep M.
    Bruix, Jordi
    [J]. LANCET, 2012, 379 (9822) : 1245 - 1255